Maunsell Farris Maryanne reported option exercise involving 645 shares of HAEMONETICS CORP at $95.73 for $61.7k on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
VP, Chief Accounting Officer
VP, Chief Accounting Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$61,745.85Shares × reported price
Shares traded
645Common Stock
Price per share
$95.73Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
7,955Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 4:16 PM ET2-day reporting delay
Accession
0000313143-26-000155Code M · Transaction 400637
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Sell836$120.99−$101,147.64Trade 400640
Nov 11, 2026Option exercise1,068$89.16$95,222.88Trade 400636
Nov 11, 2026Option exercise433$70.31$30,444.23Trade 400638
Nov 11, 2026Option exercise1,068$0.00$0Trade 400641
Nov 11, 2026Option exercise645$0.00$0Trade 400642
Nov 11, 2026Option exercise433$0.00$0Trade 400643
Nov 11, 2026Tax withholding1,724$121.10−$208,776.40Trade 400639
8 transaction rows in this filing. Joint filers share the same rows.

HAE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
HAE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago +3.6%1d ago −0.5%
Returns since7d30d90d180d1y

Footnotes in full

F1: This number includes unvested restricted stock units ("RSUs") previously reported. F2: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.